This website uses cookies

Read our Privacy policy and Terms of use for more information.

Clinical Question

Among lung transplant recipients participating in outpatient pulmonary rehabilitation, how much does six-minute walk distance change between program intake and discharge, and which factors are associated with that change?

TL;DR

❝

I just finished two weeks on my transplant rotation, and it got me thinking about what recovery actually means after someone receives new lungs. The operation can change the trajectory of a patient's lung disease, but it doesn't immediately restore the strength and endurance lost before and during hospitalization.

In a single-center cohort of 367 lung transplant recipients who enrolled in outpatient pulmonary rehabilitation, 286 had both intake and discharge six-minute walk tests. Among those with both measurements, the median improvement was 171 meters, or 61% relative to baseline.

While this is an encouraging functional outcome, it was not a randomized trial, and there was no group that recovered without rehabilitation. We can't attribute the entire improvement to rehab, separate it from natural post-transplant recovery, or conclude from this study that rehab reduces readmissions, saves money, or prolongs survival.

The results reinforce why we should make rehabilitation a reliable part of post-transplant recovery—and why we need to pay as much attention to getting patients into and through a program as we do to writing the referral.

The Deets

I've written before about how underused pulmonary rehabilitation is in COPD. The populations are different, but the larger question is the same: what happens when a treatment that can help patients function better is difficult to access?

After lung transplantation, patients may still be dealing with muscle weakness, deconditioning, nutritional challenges, and the demands of a complicated recovery. Pulmonary rehab brings supervised exercise, education, and support together to address some of those needs.

Bachmann and colleagues looked at a practical outpatient model rather than an experimental rehabilitation protocol. They linked Vanderbilt's pulmonary rehabilitation registry with transplant registry data for patients enrolled between 2013 and 2025.

The program was designed around a standard 12-week, 36-session model. Patients generally attended three one-hour sessions per week, with individually prescribed aerobic and resistance exercise, education, and psychosocial support. The cohort included patients with different insurance coverage; the program's Medicare-style structure does not mean all participants had Medicare.

Patients were typically referred at hospital discharge. Across the cohort, the median time from discharge to rehab initiation was six days. The center required recipients to remain locally for at least three months after discharge and coordinated housing and logistical support for patients from outside the area. That's important context when we think about whether another center could reproduce these results.

Study Snapshot

  • Design: Single-center, observational cohort using linked rehabilitation and transplant registry data

  • Population: 367 lung transplant recipients enrolled in their first post-transplant outpatient rehabilitation episode within one year of discharge

  • Outcome: Change in six-minute walk distance from rehab intake to discharge

  • Paired walk tests: 286 of 367 participants (77.9%)

  • Program: Supervised outpatient rehabilitation, typically three sessions per week over 12 weeks

  • Analysis: Multivariable regression with inverse probability weighting for discharge-test completion, multiple imputation for missing variables, and exploratory machine learning

What They Found

Primary Outcome

Among patients who completed both assessments:

Measure

Result

Median intake six-minute walk distance

285.3 meters

Median discharge six-minute walk distance

475.5 meters

Median individual improvement

170.7 meters (IQR, 125.0–236.5)

Median relative improvement

61.2% (IQR, 36.5%–102.5%)

Median number of sessions attended

25 (IQR, 23.8–34)

The difference between the two group medians is not the median individual change, which is calculated from each patient's paired measurements. And completing a discharge test does not necessarily mean a patient attended all 36 planned sessions.

Walking farther in six minutes is a useful measure of exercise capacity, though it doesn't tell us on its own how much easier a patient finds daily activities or how durable the gains will be.

The authors note that the median gain exceeds commonly cited clinically important difference thresholds for COPD and idiopathic pulmonary fibrosis. Those thresholds were not established specifically for lung transplant recipients, so they provide context—not a validated transplant-specific benchmark.

Who Improved the Most?

Lower walk distance at rehab intake was associated with a larger subsequent gain. In the adjusted, weighted model, each 100-meter higher intake distance was associated with approximately 60 meters less improvement.

I wouldn't interpret that as a precise prediction for an individual patient. Someone starting lower may have more room to improve (my first thought), and statistical regression to the mean and the mathematical relationship between baseline distance and change can contribute to the association.

The practical point is more modest: a low walk distance after transplant should not automatically make us assume a patient has little rehabilitation potential (it may be the opposite). This study doesn't tell us which severely impaired patients will improve, and it only includes people who made it into the program.

In a sensitivity analysis of 212 participants with available Lung Allocation Scores, the score was not significantly associated with walk-distance improvement. Functional status at transplant also wasn't significantly associated with improvement in the main model. Neither result proves that pre-transplant illness has no influence on recovery or that potential is uniform across patients.

The Lung Allocation Score was replaced by the Composite Allocation Score in 2023, so the analysis also reflects an older allocation framework.

What Bothers Me

  • No comparison group. Everyone in the cohort participated in rehab. Recovery from surgery, medical care, the passage of time, and rehabilitation occurred together, so the study can't isolate the effect of rehab itself.

  • Missing discharge tests matter. Eighty-one participants—22%—did not have a discharge walk test. They had lower baseline walk distances and longer hospital stays than those with paired tests; five died within 90 days of enrollment. A missing discharge test is not necessarily the same as dropping out of rehab, and these results shouldn't be presented as outcomes for every enrollee.

  • The setting is distinctive. This was one experienced, high-volume center with an on-site outpatient program and coordinated local housing support. Patients who never enrolled aren't represented, and the population was predominantly White. Other programs may face different barriers and see different results.

  • Long-term outcomes remain unknown. The study did not establish whether gains persisted or whether rehab reduced hospitalizations or improved survival. A single walk test at each assessment also leaves room for measurement variability and a practice effect.

Dashevsky's Dissection

I'm a big believer in making the business case for interventions that help patients function better. But we need to be precise about what this paper can and can't tell us.

This study did not measure program costs, healthcare spending, quality-adjusted life years, or an incremental cost-effectiveness ratio. It cannot establish that post-transplant rehab is cost-effective or cost-saving, even though the observed functional gains are encouraging.

There is a broader economic case for pulmonary rehabilitation in other populations. A systematic review of economic evaluations in COPD found that outpatient or primary-care rehab was cost-effective compared with usual care in the studies reviewed. That evidence is useful context, but COPD results cannot simply be transferred to lung transplant recipients, whose care, recovery, and costs are different.

The study I'd like to see next would compare post-transplant recovery strategies and measure program and patient costs alongside functional outcomes, quality of life, hospital use, and longer-term outcomes. Until then, lower readmissions or net savings are possibilities to test—not results we can claim from this cohort.

How does this impact everyone?

For patients: Rehab offers structured support for rebuilding function after a major operation. The improvements seen here are encouraging, but individual recovery varies, and this study can't promise a specific gain or determine how much improvement was caused by rehab. Access is part of the treatment plan. Can the patient get to sessions? Are housing, caregiver support, competing appointments, and out-of-pocket costs manageable? Those questions are especially relevant when a transplant center serves patients who live far away.

For pulmonologists: Plan for rehabilitation as part of the discharge and recovery pathway, with timing and exercise tailored to clinical stability and the transplant team's assessment. A referral alone isn't enough. We need to confirm that the patient can enroll, identify barriers early, and coordinate with the rehab team if complications interrupt attendance.

Don't use a poor initial walk test or a higher depression-screening score as a reason to assume rehab won't help. At the same time, address the underlying issues—including mental health needs—rather than treating exercise as a substitute for appropriate care.

For broader context, the 2023 ATS guideline strongly recommends pulmonary rehab for stable COPD, after COPD hospitalization, and for interstitial lung disease. It recognizes evidence for people recovering from lung transplantation, but transplant-specific recommendations were outside that guideline's scope.

For the health system: A successful program requires more than a discharge order. It needs trained staff, available appointments, coordination with transplant follow-up, and support for patients facing transportation or housing barriers.

We should track the full pathway: referrals, enrollment, time to first appointment, attendance, discharge testing, patient-reported outcomes, and reasons patients cannot participate. Those measures would help identify where recovery support breaks down without assuming that every missed session reflects a lack of motivation.

I've also looked at Kivo Health’s Virtual Pulmonary Rehab for COPD as a possible way to reduce travel barriers. That doesn't establish equivalence or safety for recent transplant recipients; any remote option would need appropriate transplant-specific oversight and evaluation.

In summary, lung transplant recipients with paired assessments in this outpatient rehab cohort walked substantially farther at discharge than at intake. The findings are encouraging, but an uncontrolled study cannot isolate rehab's contribution or establish its cost-effectiveness. For me, the practical challenge is making rehabilitation accessible while we build better evidence about its long-term clinical and economic value.

Bachmann JM, et al. “Factors Associated with 6-Minute Walk Distance Improvement During Outpatient Pulmonary Rehabilitation After Lung Transplantation.” Annals of the American Thoracic Society. Accepted manuscript, 2026. doi:10.1093/annalsats/aaoag286.